| Date Filed | Type | Description |
| 10/05/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/24/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/21/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/21/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/21/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/21/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/15/2023 |
SC 13G/A
| SUN HUNG KAI & CO LTD reports a 4.1% stake in Vicarious Surgical Inc. |
| 08/09/2023 |
SC 13D/A
| Khosla Ventures V, L.P. reports a 19% stake in Vicarious Surgical Inc. |
| 08/07/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/04/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"$45,000,000 OF SHARES OF",
"OPINION OF MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C",
"Vicarious Surgical Announces Launch of Proposed Public Offering WALTHAM, Mass, August 2, 2023 – Vicarious Surgical Inc. , a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced that it has commenced an underwritten public offering of $45.0 million of shares of its Class A common stock . All of the shares of Common Stock are being offered by Vicarious Surgical. In addition, the Company has granted the underwriters a 30-day option to purchase up to $6.75 million of additional shares of its Common Stock. Morgan Stanley & Co. LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. The proposed offering is subject to market and other conditions, and there...",
"Vicarious Surgical Announces Pricing of Public Offering WALTHAM, Mass, August 2, 2023 – Vicarious Surgical Inc. , a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced the pricing of its underwritten public offering of 45,000,000 shares of its Class A common stock at a price to the public of $1.00 per share. In addition, Vicarious Surgical has granted the underwriters a 30-day option to purchase up to an additional 6,750,000 shares of its Common Stock. Before deducting the underwriting discounts and commissions and estimated offering expenses, the Company expects to receive total gross proceeds of approximately $45.0 million, assuming no exercise of the underwriters’ option to purcha..." |
|
| 08/04/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/02/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 07/28/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/27/2023 |
8-K
| Investor presentation |
| 07/27/2023 |
8-K
| Quarterly results |
| 07/05/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/07/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/24/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/18/2023 |
8-K
| Appointed COO |
| 05/08/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/08/2023 |
8-K
| Quarterly results |
| 05/05/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/25/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/25/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/14/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 02/07/2023 |
SC 13G/A
| SUN HUNG KAI & CO LTD reports a 5.2% stake in Vicarious Surgical Inc. |
| 01/23/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/28/2022 |
SC 13G/A
| Bright Insight Holdings Ltd. reports a 4.9% stake in Vicarious Surgical Inc. |
| 12/01/2022 |
SC 13G/A
| Cadin Ltd. reports a 4.9% stake in Vicarious Surgical Inc. |
| 11/07/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/07/2022 |
8-K
| Quarterly results |
| 10/28/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 10/28/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 10/20/2022 |
8-K
| Quarterly results |
|